Organon (OGN) Stock Skyrockets 41% Following Sun Pharma’s $12B Acquisition Proposal

Key Highlights

• Sun Pharmaceutical Industries presented a binding all-cash acquisition proposal valued at $12 billion for Organon (OGN)
• Shares of OGN skyrocketed 41% to reach $8.25 on Friday, following an 18% climb to $6.91 the previous day
• The Indian pharmaceutical giant has wrapped up more than three months of comprehensive due diligence and is securing financing through JPMorgan and MUFG
• Upon completion, this transaction would represent the largest international M&A deal ever executed by an Indian pharmaceutical firm
• Shares of Sun Pharmaceutical declined 3% on the Mumbai exchange after the announcement

Shares of Organon have experienced an extraordinary two-day surge. The women’s healthcare specialist based in New Jersey saw its stock price rocket 41% on Friday morning, climbing to $8.25, building on the previous day’s impressive 18% increase. The catalyst? Reports indicating that Sun Pharmaceutical Industries had officially submitted a formal $12 billion acquisition proposal.

Organon & Co., OGN

According to India’s Economic Times, the pharmaceutical company headquartered in Mumbai has progressed past the preliminary research phase and submitted a binding, all-cash proposal. Sun Pharma’s pursuit of this acquisition has been underway for over three months.

With Organon’s present market capitalization hovering around $1.8 billion, the proposed $12 billion bid represents a significant premium above its existing market value.

Major financial institutions are facilitating the transaction’s funding structure. JPMorgan alongside Japan’s MUFG are among the international banking giants assisting Sun Pharma with its financing arrangements.

Organon’s Corporate History

Organon became an independent entity following its separation from Merck in 2021. The company specializes in women’s reproductive healthcare, birth control, and fertility treatments, while maintaining additional product lines in dermatology, neurological disorders, and cardiovascular therapeutics.

The organization has navigated challenging circumstances recently. In October 2025, former CEO Kevin Ali departed following an internal board inquiry that uncovered what the company characterized as questionable sales tactics employed to artificially boost quarterly performance metrics.

This isn’t Sun Pharma’s first attempt at acquiring Organon. Earlier in January, the Economic Times disclosed that Sun Pharma had submitted a preliminary, non-binding all-cash proposal and was gearing up to commence due diligence procedures. Friday’s development signals significant advancement beyond that initial phase.

Implications for Sun Pharmaceutical

Should this transaction reach completion, it would establish a new benchmark as the largest international acquisition in the history of India’s pharmaceutical industry—a milestone achievement for the sector.

Investors in Sun Pharmaceutical responded unfavorably to the announcement, with shares declining 3% on the Mumbai stock exchange Friday. Such market reactions are typical when acquiring companies announce substantial, leveraged acquisitions.

Both Organon and Sun Pharmaceutical declined to provide statements to media inquiries at the time of publication.

Prior to this week’s dramatic rally, OGN shares had been languishing at suppressed price levels. The consecutive gains of 18% and 41% mark a striking reversal in market perception surrounding the stock.

As of Friday morning, Sun Pharma is reportedly in the concluding phases of the acquisition process, with financing mechanisms being finalized concurrent with the binding proposal submission.